Dr. Oh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 Park Plaza
Suite 1750
Irvine, CA 92614Phone+1 949-538-2289
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1990 - 1995
Rush University Medical CenterResidency, Pediatrics, 1987 - 1990
McGaw Medical Center of Northwestern UniversityFellowship, Neurology, 1984 - 1987
Kyung Hee University College of MedicineClass of 1983, MD
Certifications & Licensure
CA State Medical License 1993 - 2025
MD State Medical License 2003 - 2003
IL State Medical License 1988 - 1993- American Board of Allergy and Immunology Allergy & Immunology
Publications & Presentations
PubMed
- 99 citationsSafety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies...Joseph M. Parker, Chad K. Oh, Craig LaForce, S. David Miller, David S. Pearlman
BMC Pulmonary Medicine. 2011-02-28 - 695 citationsIdentification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an a...Hiroshi Nagata, Alexandra S. Worobec, Chad K. Oh, Badrul A. Chowdhury, Susan Tannenbaum
Proceedings of the National Academy of Sciences of the United States of America. 1995-11-07 - 152 citationsIL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand.Yoseph A. Mekori, Chad K. Oh, D D Metcalfe
Journal of Immunology. 1993-10-01
Press Mentions
Image-Guided Superficial Radiotherapy Is 99.3 Percent Effective in Treating Common Skin Cancers Without Surgery, Study SuggestsSeptember 10th, 2021- AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic IndicationsJune 9th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
